Cell-based non-invasive prenatal testing for monogenic disorders: confirmation of unaffected fetuses following preimplantation genetic testing

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Christian Liebst Frisk Toft, Aalborg University, Aalborg Universitetshospital
  • ,
  • Hans Jakob Ingerslev
  • Ulrik Schiøler Kesmodel
  • Lotte Hatt, ARCEDI Biotech ApS
  • ,
  • Ripudaman Singh, ARCEDI Biotech ApS
  • ,
  • Katarina Ravn, ARCEDI Biotech ApS
  • ,
  • Bolette Hestbek Nicolaisen, ARCEDI Biotech ApS
  • ,
  • Inga Baasch Christensen, ARCEDI Biotech ApS
  • ,
  • Mathias Kølvraa, ARCEDI Biotech ApS
  • ,
  • Line Dahl Jeppesen
  • Palle Schelde, ARCEDI Biotech ApS
  • ,
  • Ida Vogel
  • Niels Uldbjerg
  • Richard Farlie
  • ,
  • Steffen Sommer
  • ,
  • Marianne Louise Vang Østergård
  • ,
  • Ann Nygaard Jensen, Aalborg Universitetshospital
  • ,
  • Helle Mogensen, Kolding Regional Hospital
  • ,
  • Kristín Rós Kjartansdóttir
  • Birte Degn, Aalborg Universitetshospital
  • ,
  • Henrik Okkels, Aalborg Universitetshospital
  • ,
  • Anja Ernst, Aalborg Universitetshospital
  • ,
  • Inge Søkilde Pedersen, Aalborg University, Aalborg Universitetshospital

Purpose: Proof of concept of the use of cell-based non-invasive prenatal testing (cbNIPT) as an alternative to chorionic villus sampling (CVS) following preimplantation genetic testing for monogenic disorders (PGT-M). Method: PGT-M was performed by combined testing of short tandem repeat (STR) markers and direct mutation detection, followed by transfer of an unaffected embryo. Patients who opted for follow-up of PGT-M by CVS had blood sampled, from which potential fetal extravillous throphoblast cells were isolated. The cell origin and mutational status were determined by combined testing of STR markers and direct mutation detection using the same setup as during PGT. The cbNIPT results with respect to the mutational status were compared to those of genetic testing of the CVS. Results: Eight patients had blood collected between gestational weeks 10 and 13, from which 33 potential fetal cell samples were isolated. Twenty-seven out of 33 isolated cell samples were successfully tested (82%), of which 24 were of fetal origin (89%). This corresponds to a median of 2.5 successfully tested fetal cell samples per case (range 1–6). All fetal cell samples had a genetic profile identical to that of the transferred embryo confirming a pregnancy with an unaffected fetus, in accordance with the CVS results. Conclusion: These findings show that although measures are needed to enhance the test success rate and the number of cells identified, cbNIPT is a promising alternative to CVS. Trial registration number: N-20180001

Original languageEnglish
JournalJournal of Assisted Reproduction and Genetics
ISSN1058-0468
DOIs
Publication statusE-pub ahead of print - 2021

    Research areas

  • cbNIPT, PGT-M, Prenatal testing, STR markers

See relations at Aarhus University Citationformats

ID: 214957385